| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $151,094,363 | 50 | 100 |
| Fitzpatrick Jennifer | Chief Legal Officer | 0 | $0 | 3 | $1.21M | $-1.21M |
| TPG GP A, LLC | 10 percent owner | 0 | $0 | 1 | $10M | $-10M |
| RA CAPITAL MANAGEMENT, L.P. | 0 | $0 | 6 | $28.54M | $-28.54M | |
| ORBIMED ADVISORS LLC | director | 0 | $0 | 20 | $55.67M | $-55.67M |
| Thompson Peter A. | director | 0 | $0 | 20 | $55.67M | $-55.67M |
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 …
Over the last 12 months, insiders at Sionna Therapeutics, Inc. have bought $0 and sold $151.09M worth of Sionna Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sionna Therapeutics, Inc. have bought $950,400 and sold $98.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $950,400 was made by TPG GP A, LLC (10 percent owner) on 2025‑06‑27.
| 2026-09-17 | Sale | RA CAPITAL MANAGEMENT, L.P. | 3.45M 6.7355% | $6.33 | $21.84M | -34.68% | ||
| 2026-07-07 | Sale | Thompson Peter A. | director | 85,918 0.19% | $44.86 | $3.85M | -86.55% | |
| 2026-07-07 | Sale | ORBIMED ADVISORS LLC | director | 85,918 0.19% | $44.86 | $3.85M | -86.55% | |
| 2026-07-06 | Sale | Fitzpatrick Jennifer | Chief Legal Officer | 10,250 0.023% | $43.60 | $446,862 | -85.95% | |
| 2026-06-30 | Sale | Thompson Peter A. | director | 115,844 0.2654% | $45.50 | $5.27M | -85.88% | |
| 2026-06-30 | Sale | ORBIMED ADVISORS LLC | director | 115,844 0.2654% | $45.50 | $5.27M | -85.88% | |
| 2026-05-27 | Sale | Thompson Peter A. | director | 101 0.0002% | $44.49 | $4,493 | -83.19% | |
| 2026-05-27 | Sale | ORBIMED ADVISORS LLC | director | 101 0.0002% | $44.49 | $4,493 | -83.19% | |
| 2026-05-11 | Sale | Thompson Peter A. | director | 184,639 0.4127% | $46.22 | $8.53M | -54.55% | |
| 2026-05-11 | Sale | ORBIMED ADVISORS LLC | director | 184,639 0.4127% | $46.22 | $8.53M | -54.55% | |
| 2026-05-08 | Sale | Thompson Peter A. | director | 59,767 0.1339% | $44.58 | $2.66M | -24.24% | |
| 2026-05-08 | Sale | ORBIMED ADVISORS LLC | director | 59,767 0.1339% | $44.58 | $2.66M | -24.24% | |
| 2026-05-07 | Sale | Thompson Peter A. | director | 48,546 0.1111% | $44.61 | $2.17M | -22.42% | |
| 2026-05-07 | Sale | ORBIMED ADVISORS LLC | director | 48,546 0.1111% | $44.61 | $2.17M | -22.42% | |
| 2026-04-18 | Sale | Thompson Peter A. | director | 2,948 0.0067% | $44.52 | $131,245 | -14.95% | |
| 2026-04-18 | Sale | ORBIMED ADVISORS LLC | director | 2,948 0.0067% | $44.52 | $131,245 | -14.95% | |
| 2026-04-17 | Sale | Thompson Peter A. | director | 52,397 0.1195% | $44.68 | $2.34M | -16.71% | |
| 2026-04-17 | Sale | ORBIMED ADVISORS LLC | director | 52,397 0.1195% | $44.68 | $2.34M | -16.71% | |
| 2026-04-16 | Sale | Thompson Peter A. | director | 226,906 0.5071% | $45.34 | $10.29M | -19.36% | |
| 2026-04-16 | Sale | ORBIMED ADVISORS LLC | director | 226,906 0.5071% | $45.34 | $10.29M | -19.36% |
| TPG GP A, LLC | 10 percent owner | 6494962 14.3852% | $23.71M | 1 | 1 | +133.43% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$41,526,694 | 30 | 23.89% | $135.61M | |
$74,231,875 | 30 | 40.62% | $183.78M |
| Increased Positions | 68 | +106.25% | 4M | +9.9% |
| Decreased Positions | 26 | -40.63% | 3M | -7.31% |
| New Positions | 29 | New | 2M | New |
| Sold Out Positions | 7 | Sold Out | 417,434 | Sold Out |
| Total Postitions | 106 | +65.63% | 44M | +2.59% |